Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Status: Active, not recruiting

Conditions: Cancer of Bone and Connective Tissue; Cancer of Colon; Cancer of Head and Neck; Cancer of Esophagus; Fallopian Tube Cancer; Spinal Cord Cancer; Cancer of the Bile Duct; Cancer of Vulva; Bladder Cancer; Lymphoma; Cancer of Kidney; Cancer of Skin; Pancreatic Cancer; Cancer of Rectum; Breast Cancer; Cancer of Liver; Peritoneal Cancer; Lung Cancer; Cancer of Gastrointestinal Tract; Leukemia; Ovarian Cancer; Brain Cancer; Cancer of Larynx; Cancer of Endometrium; Cancer of Cervix; Cancer of Stomach; Prostate Cancer

Treatments: Other: Observation

Study type: Observational

Funder types: Industry

Identifiers

NCT05179824

TP-CA-001

Details and patient eligibility

About

Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.

Full description

The Study will collect combined clinical and molecular health information for cancer patients in the United States from multiple academic medical centers and community oncology practices. Participants who agree to join the Study will have their molecular profiling results, associated clinical health information, and longitudinal outcomes health information collected by the participating Institution for submission to Tempus. The specific goal of the Study is to create an outcomes-based dataset for future research to improve cancer treatment.

Enrollment: 1,000 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Solid or hematologic malignancy.
2. Willing and able to provide informed consent where required.
3. Has received or will receive genomic profiling.

Exclusion criteria

1. Individuals without the capacity to consent.
2. Prisoners at the time of enrollment.

Trial design

1,000 participants in 1 patient group

Group 1: Standard of Care (SOC) CGP

Description:

This group will facilitate collection of paired clinical and molecular data done as part of the standard of care or routine clinical care across a variety of institutions. The goal of Group 1 is to capture a broad range of participants to better understand longitudinal outcomes across institutions and standards of care.

Treatment:

Other: Observation